2024 | Valemetostat for patients with relapsed or refractory peripheral T-cell lymphoma (VALENTINE-PTCL01): a multicentre, open-label, single-arm, phase 2 study | LANCET ONCOLOGY |
2024 | Superior outcomes and high-risk features with carfilzomib, lenalidomide, and dexamethasone combination therapy for patients with relapsed and refractory multiple myeloma: results of the multicenter KMMWP2201 study
| HAEMATOLOGICA |
2024 | Monitoring and Treatment of Paroxysmal Nocturnal Hemoglobinuria in Patients with Aplastic Anemia in Asia: An Expert Consensus
| INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES |
2024 | Long-term efficacy and safety of tucidinostat in patients with relapsed or refractory peripheral T-cell lymphoma: final analysis of phase IIb results
| HAEMATOLOGICA |
2024 | Nation-Wide Retrospective Analysis of Allogeneic Stem Cell Transplantation in Patients with Multiple Myeloma: A Study from Korean Multiple Myeloma Working Party (KMM1913)
| CANCER RESEARCH AND TREATMENT |
2024 | Phase 3 randomized COMMODORE 1 trial: Crovalimab versus eculizumab in complement inhibitor-experienced patients with paroxysmal nocturnal hemoglobinuria | AMERICAN JOURNAL OF HEMATOLOGY |
2024 | Clinical outcomes of etoposide and cytarabine as consolidation in elderly patients with primary CNS lymphoma
| ONCOLOGIST |
2024 | Poor Mobilization-Associated Factors in Autologous Hematopoietic Stem Cell Harvest
| CANCERS |
2024 | Impact of Lactate Dehydrogenase and Hemoglobin Levels on Clinical Outcomes in Patients With Paroxysmal Nocturnal Hemoglobinuria: Results From the National Korean PNH Registry
| JOURNAL OF KOREAN MEDICAL SCIENCE |
2024 | Clinical significance of bone marrow involvement by immunoglobulin gene rearrangement in de novo diffuse large B-cell lymphoma: a multicenter retrospective study
| FRONTIERS IN ONCOLOGY |
2024 | A Multicenter Analysis of Clinical Features and Long-Term Outcomes of POEMS Syndrome in Korea
| JOURNAL OF KOREAN MEDICAL SCIENCE |
2024 | Clearing soluble MIC reverses the impaired function of natural killer cells from patients with multiple myeloma
| JOURNAL FOR IMMUNOTHERAPY OF CANCER |
2023 | Addition of danicopan to ravulizumab or eculizumab in patients with paroxysmal nocturnal haemoglobinuria and clinically significant extravascular haemolysis (ALPHA): a double-blind, randomised, phase 3 trial | LANCET HAEMATOLOGY |
2023 | Asia-Pacific Leukemia Consortium: An innovative and collaborative initiative to improve care of leukemia and related diseases in the Asia-Pacific region | ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY |
2023 | Next-Generation Sequencing of Vitreoretinal Lymphoma by Vitreous Liquid Biopsy: Diagnostic Potential and Genotype/Phenotype Correlation
| INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE |
2023 | Long-Term Efficacy and Safety of Eculizumab in Patients With Paroxysmal Nocturnal Hemoglobinuria and High Disease Burden: Real-World Data From Korea
| JOURNAL OF KOREAN MEDICAL SCIENCE |
2023 | Open-labeled, multicenter phase II study of prophylactic administration of pegylated granulocyte colony-stimulating factor in relapsed or refractory multiple myeloma who received pomalidomide-based regimens (KMM170)
| FRONTIERS IN ONCOLOGY |
2023 | Isatuximab Plus Carfilzomib and Dexamethasone in East Asian Patients With Relapsed Multiple Myeloma: Updated IKEMA Subgroup Analysis
| CLINICAL LYMPHOMA MYELOMA & LEUKEMIA |
2023 | Intensified First Cycle of Rituximab Plus Eight Cycles of Cyclophosphamide, Doxorubicin, Vincristine, and Prednisolone with Rituximab Chemotherapy for Advanced-Stage or Bulky Diffuse Large B-Cell Lymphoma: A Multicenter Phase II Consortium for Improving Survival of Lymphoma (CISL) Study
| CANCER RESEARCH AND TREATMENT |
2023 | Crovalimab treatment in patients with paroxysmal nocturnal haemoglobinuria: Long-term results from the phase I/II COMPOSER trial | EUROPEAN JOURNAL OF HAEMATOLOGY |
2023 | A Prospective Study of Preemptive Tenofovir Disoproxil Fumarate Therapy in HBsAg-Positive Patients With Diffuse Large B-Cell Lymphoma Receiving Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone | AMERICAN JOURNAL OF GASTROENTEROLOGY |
2023 | Real-world data for the use of emicizumab in haemophilia A patients with inhibitors - First nationwide report from Korea | HAEMOPHILIA |
2023 | Mitigating Drug-Target-Drug Complexes in Patients With Paroxysmal Nocturnal Hemoglobinuria Who Switch C5 Inhibitors | CLINICAL PHARMACOLOGY & THERAPEUTICS |
2023 | Cyclophosphamide, Bortezomib, and Dexamethasone Consolidation in Patients with Multiple Myeloma after Stem Cell Transplantation: The KMM130 Study
| CANCER RESEARCH AND TREATMENT |
2023 | Daratumumab plus bortezomib, cyclophosphamide, and dexamethasone in Asian patients with newly diagnosed AL amyloidosis: subgroup analysis of ANDROMEDA
| ANNALS OF HEMATOLOGY |
2023 | Acute coronary syndrome in antineutrophil cytoplasmic antibody-associated vasculitis: a Korean single-centre cohort study
| Journal of Rheumatic Diseases |
2023 | Oral HDAC inhibitor tucidinostat in patients with relapsed or refractory peripheral T-cell lymphoma: phase IIb results
| HAEMATOLOGICA |
2023 | Validating lactate dehydrogenase (LDH) as a component of the PLASMIC predictive tool (PLASMIC-LDH)
| BLOOD RESEARCH |
2023 | The first successful eculizumab rescue therapy of a kidney transplant recipient with atypical hemolytic uremic syndrome in South Korea: a case report
| Korean Journal of Transplantation |
2023 | Outcomes in Refractory Diffuse Large B-Cell Lymphoma: Results from Two Prospective Korean Cohorts
| CANCER RESEARCH AND TREATMENT |
2023 | DRP1 Inhibition Enhances Venetoclax-Induced Mitochondrial Apoptosis in TP53-Mutated Acute Myeloid Leukemia Cells through BAX/BAK Activation
| CANCERS |
2022 | Isatuximab in Combination with Lenalidomide and Dexamethasone in Patients with High-Risk Smoldering Multiple Myeloma: Updated Safety Run-in Results from the Randomized Phase 3 Ithaca Study | BLOOD |
2022 | Interim Results of the Phase 1 Study of Tnb-486, a Novel CD19xCD3 T-Cell Engager, in Patients with Relapsed/Refractory (R/R) B-NHL | BLOOD |
2022 | Impact of BCL2/MYC Protein Dual Expression and Other Clinical Factors on the Risk of Central Nervous System Progression in Patients with Primary Breast Diffuse Large B-Cell Lymphoma | BLOOD |
2022 | Carfilzomib Use Among Patients with Relapsed/Refractory Multiple Myeloma in the Asia Pacific Region: Characteristics and Outcomes By Regimen from a Prospective, Real-World Study | BLOOD |
2022 | Isatuximab plus carfilzomib and dexamethasone in East Asian patients with relapsed multiple myeloma: IKEMA subgroup analysis | INTERNATIONAL JOURNAL OF HEMATOLOGY |
2022 | Phase II trial of daratumumab with DCEP in relapsed/refractory multiple myeloma patients with extramedullary disease
| JOURNAL OF HEMATOLOGY & ONCOLOGY |
2022 | Subgroup analysis based on cytogenetic risk in patients with relapsed or refractory multiple myeloma in the CANDOR study | BRITISH JOURNAL OF HAEMATOLOGY |
2022 | Early diagnosis of Gaucher disease in Korean patients with unexplained splenomegaly: a multicenter observational study
| BLOOD RESEARCH |
2022 | 국내 Human Research Protection Program 도입 과정과 발전 방향에 대한 고찰
| Journal of KAIRB |
2022 | Busulfan and thiotepa as a conditioning regimen for autologous stem cell transplantation in patients with multiple myeloma: A study of the Korean Multiple Myeloma Working Party (KMMWP-1801 study)
| FRONTIERS IN ONCOLOGY |
2022 | Isatuximab-Pomalidomide-Dexamethasone Versus Pomalidomide-Dexamethasone in East Asian Patients With Relapsed/Refractory Multiple Myeloma: ICARIA-MM Subgroup Analysis
| CLINICAL LYMPHOMA MYELOMA & LEUKEMIA |
2022 | Real-world data on prognostic value of measurable residual disease assessment by fragment analysis or next-generation sequencing in multiple myeloma | BRITISH JOURNAL OF HAEMATOLOGY |
2022 | Characteristics and clinical outcome of high-risk multiple myeloma patients in Korea (KMM 1805) | INTERNATIONAL JOURNAL OF HEMATOLOGY |
2022 | Cytogenetic testing by fluorescence in situ hybridization is improved by plasma cell sorting in multiple myeloma
| SCIENTIFIC REPORTS |
2022 | An overview of treatment options for patients with relapsed/refractory multiple myeloma and renal impairment
| THERAPEUTIC ADVANCES IN HEMATOLOGY |
2022 | Predictive Factors of Event-Free Survival at 24 Months in Patients with Peripheral T-Cell Lymphoma: A Retrospective Study
| CANCER RESEARCH AND TREATMENT |
2022 | Management of immune thrombocytopenia: 2022 update of Korean experts recommendations
| BLOOD RESEARCH |
2022 | Multicenter, phase II study of response-adapted lenalidomide-based therapy for transplant-ineligible patients with newly diagnosed multiple myeloma without high-risk features
| CURRENT PROBLEMS IN CANCER |
2022 | Limited benefits of thalidomide and dexamethasone maintenance after autologous stem cell transplantation in newly diagnosed multiple myeloma patients: a prospective phase II multi-center study in Korea
| CURRENT PROBLEMS IN CANCER |